现货大促销,价格低至8折起,量大更优惠,详细咨询客服
全部分类
全部分类
  • WIN 55,212-2 Mesylate
WIN 55,212-2 Mesylate的可视化放大

WIN 55,212-2 Mesylate

A potent CB1 and CB2 receptor agonist

原价
¥437-4962
价格
350-3970
WIN 55,212-2 Mesylate的二维码

所有产品仅用于科学研究,我们不为任何个人用途提供产品和服务

询价有惊喜,量大更优惠 点击这里给我发消息

  • 库存: 现货
可选包装 >>>
首页
  • 货号: ajce60112
  • CAS: 131543-23-2
  • 别名: (R)-(+)-WIN55,212-2甲磺酸盐,(R)-(+)-WIN 55212
  • 分子式: C28H30N2O6S
  • 分子量: 522.61
  • 纯度: >98%
  • 溶解度: DMSO: ≥ 34 mg/mL (65.06 mM)
  • 储存: Store at -20°C
  • 库存: 现货

Background

(+)-WIN 55,212-2 (mesylate) is a potent aminoalkylindole cannabinoid (CB) receptor agonist with Ki values of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively.1 In primary cultures of rat cerebral cortex neurons, (+)-WIN 55,212-2 (mesylate) (0.01-100 nM) increases extracellular glutamate levels, displaying a bell-shaped concentration-response curve.2 This effect is fully counteracted by rimonabant at a concentration of 10 nM, by decreasing Ca2+ concentrations below 0.2 mM, or by the IP3 receptor antagonist xestospongin C at a concentration of 1 ?M. (+)-WIN 55,212-2 (mesylate) induces release of the proinflammatory neuropeptide CGRP from trigeminal ganglion (TG) neurons in a calcium-dependent manner with an EC50 value of 26 ?M.3


1.Felder, C.C., Joyce, K.E., Briley, E.M., et al.Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptorsMol. Pharmacol.48(3)443-450(1995) 2.Ferraro, L., Tomasini, M.C., Gessa, G.L., et al.The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: An in vivo and in vitro studyCereb. Cortex11(8)728-733(2001) 3.Price, T.J., Patwardhan, A., Akopian, A.N., et al.Cannabinoid receptor-independent actions of the aminoalkylindole WIN 55,212-2 on trigeminal sensory neuronsBr. J. Pharmacol.142(2)257-266(2004)

Protocol

Animal experiment:

In experiment 1, different doses of WIN 55,212-2 (0.5, 1, 3, 5, 10 and 15 mg/kg) are injected 60 min prior to the determination of clonic seizure threshold induced by intravenous administration of PTZ solution. Control animals receive the same volume of the vehicle (1% aqueous solution of DMSO). The doses and time point are chosen on the basis of pilot studies. In experiment 2, in order to confirm the anticonvulsant effects of pioglitazone, different doses (10, 20, 40 and 80 mg/kg) are administered 4 h prior to PTZ in distinct groups of mice. The corresponding control groupreceive the appropriate vehicle (CMC 1%) at the same time point. In experiment 3, The additive anti epileptic effects of WIN 55,212-2 and pioglitazone are examined; mice receive acute administration of pioglitazone (10 or 20 mg/kg) 3 h before WIN 55,212-2 (0.5 or 1 mg/kg) and 4 h before PTZ.

参考文献:

[1]. Felder CC, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 1995 Sep;48(3):443-50.
[2]. Ferraro L, et al. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb Cortex. 2001 Aug;11(8):728-33.
[3]. Price TJ, et al. Cannabinoid receptor-independent actions of the aminoalkylindole WIN 55,212-2 on trigeminal sensory neurons. Br J Pharmacol. 2004 May;142(2):257-66.
[4]. Payandemehr B, et al. Involvement of PPAR receptors in the anticonvulsant effects of a cannabinoid agonist, WIN 55,212-2. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Mar 3;57:140-5

动态评分

0.0

没有评分数据
没有评价数据
一键回到顶部
展开 收缩
安捷凯在线客服